BRD4 and cancer: Brd4 is a validated drug target for various cancer implications,[12] whilst VHL has routinely been recruited by PROTACs for the degradation of a diverse range of targets both in vitro and in vivo.[5a, 13] GNE‐987 has previously been validated as a more potent Brd4 degraded in vitro than standard PROTACs MZ1 and ARV‐771.